Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium  AACR Conference on Molecular Diagnostics - 2008
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 52, 4663-4671, September 1, 1992]
© 1992 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Neubauer, B. L.
Right arrow Articles by Merriman, R. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Neubauer, B. L.
Right arrow Articles by Merriman, R. L.

Comparative Antitumor Effects of Hormonal Ablation, Estrogen Agonist, Estrogen Cytotoxic Derivative, and Antiestrogen in the PAIII Rat Prostatic Adenocarcinoma

Blake Lee Neubauer1, Kevin L. Best, Robin L. Goode, Mark L. Heiman, Dennis M. Hoover, David W. Robertson, Michael F. Sarosdy, Carl J. Shaar, Lee R. Tanzer and Ronald L. Merriman

The Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285 [B. L. N., K. L. B., R. L. G., M. L. H., D. M. H., D. W. R., C. J. S., L. R. T., R. L. M.], and Department of Surgery/Urology, University of Texas Health Sciences Center, San Antonio, Texas 78284 [M. F. S.]

The effects of hormonal ablation, estrogen, estrogen-derived cytotoxic agent, and estrogen antagonist therapies used clinically were evaluated on in vitro colony formation, in vivo growth, and lymphatic and pulmonary metastasis of the PAIII tumor. Ventral prostatic and seminal vesicle weights were evaluated in the same animals to assess androgen-related responses. Estradiol, estramustine phosphate, and testosterone had no effects on PAIII colony formation in vitro. Castration, hypophysectomy, estradiol benzoate, and estramustine phosphate treatment of PAIII-bearing Lobund Wistar rats produced significant (P < 0.05) regression of male accessory sex organs. Of these treatments, only hypophysectomy had significant (P < 0.05) inhibitory effects on primary PAIII growth and lymphatic and pulmonary metastasis. LY117018 [6-hydroxy-2-(p-hydroxyphenyl)benzo(b)thien-3-yl-p-2-(1-pyrrolidinyl)ethoxy phenyl ketone] has antiestrogenic activity but produces no significant agonist responses. LY117018 had no effect upon PAIII colony formation in vitro. Following s.c. implantation of PAIII cells, LY117018 (2.0, 10.0, or 20.0 mg/kg s.c.) had no effect on primary tumor growth in the tail. In vitro LY117018 administration produced marked antimetastatic effects. In a dose-dependent manner, LY117018 inhibited PAIII metastasis to the gluteal (97%) and iliac lymph nodes (88%) (P < 0.05 for both). LY117018 also maximally inhibited pulmonary metastasis by 86% (P < 0.05). Maximal regression of 42% for ventral prostatic and 35% for seminal vesicle weights were also seen after LY117018 administration (P < 0.05 for both). Co-administration of estradiol benzoate had no antagonistic effect upon the antitumor responses produced by LY117018. The mechanism of action of LY117018 is not known. The failure of estradiol benzoate to affect PAIII growth and metastasis supports the contention that the responses to LY117018 are not attributable to simple antagonism of estrogen action. LY117018 may be exerting its antitumor effects through autocrine, paracrine, or endocrine mechanisms. LY117018 represents a class of agents with potential utility in treating metastatic cancer of the prostate.

1 To whom requests for reprints should be addressed, at CNS/GI/GU Research 0815, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285.

Received 1/24/92. Accepted 6/16/92.




This article has been cited by other articles:


Home page
Exp. Biol. Med.Home page
M. Pollard and M. A. Suckow
Hormone-Refractory Prostate Cancer in the Lobund-Wistar Rat
Experimental Biology and Medicine, September 1, 2005; 230(8): 520 - 526.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
B. L. Neubauer, A. M. McNulty, M. Chedid, K. Chen, R. L. Goode, M. A. Johnson, C. D. Jones, V. Krishnan, R. Lynch, H. E. Osborne, et al.
The Selective Estrogen Receptor Modulator Trioxifene (LY133314) Inhibits Metastasis and Extends Survival in the PAIII Rat Prostatic Carcinoma Model
Cancer Res., September 15, 2003; 63(18): 6056 - 6062.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
M. Omura, R. Ogata, K. Kubo, Y. Shimasaki, S. Aou, Y. Oshima, A. Tanaka, M. Hirata, Y. Makita, and N. Inoue
Two-Generation Reproductive Toxicity Study of Tributyltin Chloride in Male Rats
Toxicol. Sci., December 1, 2001; 64(2): 224 - 232.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1992 by the American Association for Cancer Research.